[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332212-105":59,"doc-detail-332212-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-advances-of-lipid-nanoparticles-in-the-treatment-of-colorectal-cancer","Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer","","Colorectal cancer (CRC) is a major gastrointestinal malignancy with limited effectiveness of current metastatic therapies due to adverse reactions and drug resistance. Lipid nanoparticles (LNPs) are reviewed as a promising nanotechnology-based drug delivery system that can be tailored by formulation changes for selective delivery to CRC tissues. The review covers composition and targeting strategies and summarizes applications including drug delivery, thermal therapy, and nucleic acid gene therapy, noting benefits, limitations, and future prospects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-advances-of-lipid-nanoparticles-in-the-treatment-of-colorectal-cancer/332212/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-advances-of-lipid-nanoparticles-in-the-treatment-of-colorectal-cancer/332212.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are current metastatic colorectal cancer therapies limited in practice?","Question",{"text":112,"@type":113},"They are constrained by adverse reactions and the development of drug resistance, which restricts clinical use and can impair patients’ quality of life.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do lipid nanoparticles (LNPs) improve drug delivery for colorectal cancer?",{"text":117,"@type":113},"LNP formulations can be modified to match CRC biological characteristics, enabling selective delivery to cancer tissues and addressing issues like poor water solubility and nonspecific biodistribution.",{"name":119,"@type":110,"acceptedAnswer":120},"What applications of LNPs in CRC treatment does the review summarize?",{"text":121,"@type":113},"The review summarizes nanoparticle applications including drug delivery, thermal therapy, and nucleic acid-based gene therapy, with examples.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332212,1790192974,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","International Journal of Nanomedicine Dovepress  \nopen access to scientific and medical research  \n Open Access Full Text Article REVIEW  \nResearch Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer  \nJunyi Zhang 1 , Kamran Ali 1 , Jianwei Wang 1 , 2  \n1Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, People’s Republic of China; 2Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China  \nCorrespondence: Jianwei Wang, Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China, Email [sypzju@zju.edu.cn](sypzju@zju.edu.cn)  \n\n| Abstract: Colorectal cancer (CRC) is a common type of gastrointestinal tract (GIT) cancer and poses an enormous threat to human health. Current strategies for metastatic colorectal cancer (mCRC) therapy primarily focus on chemotherapy, targeted therapy, immunotherapy, and radiotherapy; however, their adverse reactions and drug resistance limit their clinical application. Advances in nanotechnology have rendered lipid nanoparticles (LNPs) a promising nanomaterial-based drug delivery system for CRC therapy. LNPs can adapt to the biological characteristics of CRC by modifying their formulation, enabling the selective delivery of drugs to cancer tissues. They overcome the limitations of traditional therapies, such as poor water solubility, nonspecific biodistribution, and limited bioavailability. Herein, we review the composition and targeting strategies of LNPs for CRC therapy. Subsequently, the applications of these nanoparticles in CRC treatment including drug delivery, thermal therapy, and nucleic acid-based gene therapy are summarized with examples provided. The last section provides a glimpse into the advantages, current limitations, and prospects of LNPs in the treatment of CRC.\u003Cbr>Keywords: lipid nanoparticles, colorectal cancer, tumor targeting, drug delivery, nanotechnology |\n| --- |\n| Introduction\u003Cbr>Globally, colorectal cancer (CRC) is the third most frequently diagnosed malignancy and the second leading cause of cancer death.1–3 Most CRC cases arise sporadically, while approximately 35% of cases are attributed to heritable factors.4 It is believed that the vast majority of CRCs follow the adenoma-carcinoma sequence and serrated polyp-carcinoma sequence, largely due to genetic aberrations at the cellular level.5–7 Currently, the principal therapeutic approaches for CRC include surgical intervention, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.8–10 However, the chemotherapeutic and targeted agents currently in use are associated with substantial treatment-related toxicities.11 These adverse effects significantly impair patients’ quality of life, constrain dosage limits, and may even cause the termination of treatment.12–14 Consequently, there is an urgent need to devise treatment strategies that minimize the non-specific distribution of drugs and mitigate toxic side effects, thereby improving both the quality of life and prognosis of CRC patients.\u003Cbr>In response to these challenges, colon-specific drug delivery systems (CDDS), particularly those employing nanotechnology for colon targeting, have been tailored to meet the biological characteristics and clinical demands of CRC.15–17 Among the various existing drug carriers, nanoparticles (NPs) can enhance drug stability and solubility, facilitate transmembrane transport, and extend circulation time, thereby improving both safety and efficacy.18 Drugs absorbed in the colon are taken up by the intestinal mucosa and subsequently enter systemic circulation vi","cbCaipTU9Qh2Fxnw","https://ap.wps.com/l/cbCaipTU9Qh2Fxnw","pdf",7329755,23,"English","# Abstract\n# Introduction\n## Clinical burden and current therapeutic limits\n## Colon-specific drug delivery systems and nanoparticle advantages\n## Targeting and controlled-release mechanisms","[{\"question\":\"Why are current metastatic colorectal cancer therapies limited in practice?\",\"answer\":\"They are constrained by adverse reactions and the development of drug resistance, which restricts clinical use and can impair patients’ quality of life.\"},{\"question\":\"How do lipid nanoparticles (LNPs) improve drug delivery for colorectal cancer?\",\"answer\":\"LNP formulations can be modified to match CRC biological characteristics, enabling selective delivery to cancer tissues and addressing issues like poor water solubility and nonspecific biodistribution.\"},{\"question\":\"What applications of LNPs in CRC treatment does the review summarize?\",\"answer\":\"The review summarizes nanoparticle applications including drug delivery, thermal therapy, and nucleic acid-based gene therapy, with examples.\"}]","Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer | PDF",1789997346,58]